Moderna says new RSV vaccine 84% effective in older adults
A vaccine against respiratory syncytial virus (RSV) being developed by Moderna is 83.7% effective at preventing respiratory disease in older adults, the biotechnology company announced on Tuesday. What is RSV? RSV is a respiratory virus that usually causes mild, cold-like symptoms, but can cause serious complications in infants and older adults. According to the US […]
Continue Reading